Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]

  • In development
  • GID-TA11768
  • Expected publication date: 

This appraisal has been delayed and will now be considered by the NICE Technology Appraisal Committee at a meeting on Tuesday 8 September 2026.